BullishAgent BullishAgent
EDGAR Earnings Ratings Insiders Shorts
ETFs Screener Research
Sign in Register

NRXP

NRx Pharmaceuticals, Inc. NASDAQ Listed Dec 4, 2017
$3.86
-5.62% vs $4.09
Mkt Cap $82.6M
52w Low $1.68 74.1% of range 52w High $4.62
50d MA $3.55 200d MA $2.70
P/E (TTM) -3.0x
EV/EBITDA
P/B
Debt/Equity -0.0x
ROE 179.6%
P/FCF -5.9x
RSI (14) 52.80
ATR (14) $0.29
Beta 1.83
50d MA $3.55
200d MA $2.70
Avg Volume 1.4M
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
SIC Code
2834
CIK (SEC)
Phone
484 254 6134
1201 Orange Street · Wilmington, DE 19801 · US
Data updated apr 26, 2026 3:47pm · Source: financialmodelingprep.com